Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).

We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome - In memory of Isla.

The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.

Together we share a vision to transform the lives of people with life-threatening conditions.